CD24 and acute respiratory distress syndrome: In the context of addressing the urgent need for treatment options for Acute Respiratory Distress Syndrome (ARDS), research has pointed towards the promising safety and efficacy of EXO-CD24 in over 180 ARDS patients across phase 1b/2a and phase 2b studies.